☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
hutchmed
HUTCHMED Reports the NMPA’s NDA Acceptance of Tazemetostat for Treating Follicular Lymphoma
July 4, 2024
HUTCHMED Features the P-III (ESLIM-01) Study Data of Sovleplenib for Primary Immune Thrombocytopenia at EHA 2024
June 17, 2024
HUTCHMED Reports the P-III Trial Data and will Highlight Hematological Malignancy Programs at the EHA 2024
May 17, 2024
HUTCHMED Commences the P-II/III Study of Surufatinib Plus Camrelizumab for Pancreatic Ductal Adenocarcinoma
May 15, 2024
HUTCHMED Commences the P-III (RAPHAEL) Study of HMPL-306 for Treating Acute Myeloid Leukemia in China
May 14, 2024
The NMPA Accepts HUTCHMED and Innovent’s NDA for Fruquintinib Plus Sintilimab with Priority Review to Treat Endometrial Cancer
April 2, 2024
Load more...
Back to Home
Modal title
×
Modal body text goes here.